A Nationwide Children’s Hospital spinoff that’s developing a probiotic treatment for the leading cause of death from gastrointestinal disease in premature infants has raised $1.8 million from a group of funds including Rev1 Ventures.
Indianapolis-based Scioto Biosciences Inc. raised the round with Indiana-based BioCrossroads and Elevate Ventures, along with Columbus-based Rev1. It previously had $380,000 in grants from the National Institutes of Health and the state of Indiana.
Click here to read the complete article.
Story excerpt provided by Columbus Business First.
Written by Carrie Ghose.
Originally published May 22, 2018.